United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company dedicated to developing pharmaceuticals and technologies for chronic and life-threatening diseases, with a significant focus on lung diseases and organ transplantation. The company's mission is to provide a brighter future for patients through novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Co-headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, United Therapeutics operates as a Public Benefit Corporation (PBC), aligning its corporate structure with its patient-driven mission.

The company's key product portfolio includes therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), such as Tyvaso DPI, Tyvaso, Remodulin, Orenitram, and Adcirca. Additionally, United Therapeutics markets Unituxin for the treatment of high-risk neuroblastoma. Beyond pharmaceuticals, the company is actively engaged in organ manufacturing programs, including xenotransplantation and 3D bio-printing, with the goal of addressing the critical shortage of transplantable organs.

Founded by Chairperson and CEO Martine Rothblatt, United Therapeutics became the first publicly traded biotech or pharmaceutical company to convert to a Public Benefit Corporation in 2021. Recent notable developments include the U.S. Food and Drug Administration granting Regenerative Medicine Advanced Therapy designation to its investigational liver device, miroliverELAP, and positive results from the TETON-1 study for Tyvaso in idiopathic pulmonary fibrosis. The company also announced a $2 billion stock repurchase authorization in March 2026 and has expanded its organ manufacturing capabilities through acquisitions like Miromatrix Medical Inc. and IVIVA Medical in late 2023.